Author's response to reviews

Title: SNP-SNP Interactions in Breast Cancer Susceptibility

Authors:

Venus U Onay (onay@mshri.on.ca)
Laurent Briollais (laurent@mshri.on.ca)
Julia A Knight (knight@mshri.on.ca)
Ellen Shi (jugingshi@hotmail.com)
Yuanyuan Wang (annywan@hotmail.com)
Sean Wells (sean@mshri.on.ca)
Hong Li (li@mshri.on.ca)
Isaac Rajendram (idr1978@hotmail.com)
Irene L Andrilis (andrilis@mshri.on.ca)
Hilmi Ozcelik (ozcelik@mshri.on.ca)

Version: 7 Date: 14 April 2006

Author's response to reviews: see over
Dear Editor,

We would like to thank you for accepting our manuscript MS1523829166824828 for publication in BMC Cancer. We also would like to express our appreciation for the input provided by the two reviewers, which helped us to improve our manuscript considerably. We have completed the format changes and additions in agreement with the journal’s general rules of manuscript submission. We have added to the Methods section the sentence “Written informed consent was obtained from all subjects, and the study protocol was approved by Mount Sinai Hospital Research Ethics Board”. We are attaching the mentioned approval letter in this file as well as a letter from Elsevier granting permission to use a copyrighted material (Figure 2) in our manuscript.

Sincerely Yours,

Hilmi Ozcelik, Ph.D.
Mount Sinai Hospital,
600 University Ave., Rm 992A,
Toronto, Ontario M5G 1X5
Tel: 416-586-4996, Fax: 416-586-8869
email: ozcelik@mshri.on.ca.
Notification of REB Continued Approval

Date: April 6, 2006

To: Dr. Irene Andruis
Mount Sinai Hospital
Room 984
600 University Avenue
Toronto, Ontario

Re: 02-0076-U
Ontario Registry for Studies of Familial Breast Cancer

REB Review Type: Expedited
REB Initial Approval Date: 20 April, 2002
REB Expiry Date: 20 April, 2007

Consent Forms Currently Approved for Use:
Stage 1 (dated 11 Apr 05) Stage 2, Proband (dated 11 Apr 05)
Stage 2, Kin (dated 11 Apr 05) Stage 3, Blood and Tissue (dated 13 Dec 05)

The above-named study has received continued approval from the Mount Sinai Hospital Research Ethics Board until the expiry date noted above. If the study is expected to continue beyond the expiry date, you are responsible for ensuring the study receives re-approval. The REB must also be notified of the completion or termination of this study and a final report provided.

If, during the course of the research, there are any serious adverse events, confidentiality concerns, changes in the approved project, or any new information that must be considered with respect to the project, these should be brought to the immediate attention of the REB. In the event of a privacy breach, you are responsible for reporting the breach to the MSH REB and the MSH Corporate Privacy Office (in accordance with Ontario health privacy legislation – Personal Health Information Protection Act, 2004). Additionally, the MSH REB requires reports of inappropriate/unauthorized use of the information. As the Principal Investigator, you are responsible for the ethical conduct of this study.


Sincerely,

Kathleen Austin, B.Sc., B.A., M.A.
Coordinator, Research Ethics Board

For: Ronald Hesegrave, Ph.D.
Chair, Mount Sinai Hospital Research Ethics Board
Notification of REB Administrative Change Approval

Date: April 6, 2006

To: Dr. Irene Andritis
Mount Sinai Hospital
Room 984
600 University Avenue
Toronto, Ontario

Re: 02-0076-U
Ontario Registry for Studies of Familial Breast Cancer

REB Review Type: Expedited
REB Initial Approval Date: 20 April, 2002
REB Expiry Date: 20 April, 2007
REB Administrative Change Approval Date: April 6, 2006
Documents Approved: Stage 3, Tissue/Blood Consent (dated 13 Dec 05)


Best wishes for the successful completion of your project.

Sincerely,

Kathleen Austin, B.Sc., B.A., M.A.
Coordinator, Research Ethics Board

For: Ronald Heslegrave, Ph.D.
Chair, Mount Sinai Hospital Research Ethics Board
12 April 2006

Dr Ummiye Venus Onay
Mount Sinai Hospital

onay@mshri.on.ca

Dear Dr Onay

**MUTATION RESEARCH, Vol 544, 2003, pp 9-41, Mitrakus et al, “Molecular epidemiology...” Figure 3 only**

Proposed Use: For publication in BMC Cancer.

As per your letter dated 11 April 2006, we hereby grant you permission to reproduce the aforementioned material in **print and electronic format** at no charge subject to the following conditions:

1. If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies.

2. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

   “Reprinted from Publication title, Vol number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier”.

3. This permission is granted for non-exclusive world rights in all languages.

4. Reproduction of this material is granted for the purpose for which permission is hereby given, and includes use in any future editions.

Yours sincerely

C. Truter

Clare Truter
Deputy Rights Manager, S&T

*Your future requests will be handled more quickly if you complete the online form at [www.elsevier.com/permissions]*